Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Under the agreement, Searchlight Pharma (“Searchlight”), Apotex's Specialty Pharma Division, will pursue marketing authorization for Qutenza® and market and distribute Qutenza® in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties.
Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities.
“We have continuously developed Qutenza® to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US,” says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. “Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain.”
This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 pharmaceutical and consumer health products.
“Licensing the Canadian rights to Qutenza® enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets,” said Mark Nawacki, President of Searchlight. “This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care.”
Contacts
Florian DieckmannHead Global Corporate AffairsGrünenthal
Tel:+49 241 569-2555Florian.Dieckmann@grunenthal.comMedia contactApotex
media@apotex.comAbout Qutenza®
In Europe, Qutenza® is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.
Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group | Instagram: grunenthal
About Apotex and Searchlight Pharma
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets.
Learn more about us at www.apotex.com and at www.searchlightpharma.com.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
MT Raceteam entering Ligier European Series with 16 year old Marcus Terkildsen / attractive partnerships and high visibility available18.12.2025 13:28:55 CET | Press Release
Copenhagen, Dec 18, 2025 - MT Raceteam is proud to announce its 2026 entry into the prestigious Ligier European Series, where the team will compete in a state-of-the-art Ligier JS2 R supplied by 23 Events Racing. This marks an important milestone for both the team and sixteen-year-old Danish driver Marcus Terkildsen as they step into one of Europe’s most competitive championships.
NTT DATA acquires The Cloud People to expand ServiceNow expertise and strengthen global reach18.12.2025 12:00:00 CET | Press Release
Bielefeld, Germany/Oslo, Norway — December 18, 2025 — NTT DATA announces the acquisition of The Cloud People Group AS, one of the largest pure-play ServiceNow partners in Europe. Founded in 2019, The Cloud People is headquartered in Oslo, Norway, with offices across northern Europe, the USA and Brazil, and will become part of NTT DATA Business Solutions, a business unit of NTT DATA. As a leading provider of ServiceNow solutions for medium and large enterprises, The Cloud People offer a focused value proposition covering the entire ServiceNow platform. The company delivers services across multiple workflows including IT service management, incident, problem and change management, automation of routine tasks, resource planning, onboarding and offboarding of employees, as well as customer service and security operations. The acquisition of The Cloud People will add 130 active customers to NTT DATA Business Solutions’ portfolio. The Cloud People is at the forefront of ServiceNow’s AI evolu
fulfillmenttools Delivers Global Order Management Solution for DEICHMANN18.12.2025 11:02:35 CET | Press Release
fulfillmenttools will support DEICHMANN in streamlining its order processing across different channels. The platform connects and manages the retailer’s inventory and order management across several countries, online shops, physical stores, and marketplaces. Partnering with Europe’s leading footwear retailer highlights fulfillmenttools’ strong position in Order Management and demonstrates the solution’s adaptability for international commerce.
ZEISS concludes fiscal year 2024/25 with solid growth18.12.2025 11:00:00 CET | Press Release
Revenue totaled almost 12 billion euros, with EBIT at 1.552 billion euros. The segments once again presented a mixed picture. Targeted resilience measures and investments in innovative strength are the key to the future. Mixed picture in all four segments Targeted resilience measures continued Expenditure on research and development still high at 15% of revenue Current outlook challenging
Innovative Support AI “Neo” Launches in the New Customer App from PLAN-B NET ZERO12.12.2025 09:00:00 CET | Press Release
Zug/Berlin, December 12, 2025 – With “Neo”, PLAN-B NET ZERO is introducing a new generation of digital customer support: an AI that answers energy-related questions in real time, resolves requests automatically and is available around the clock. Faster, more precise and more personal than traditional service models.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom